Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Otsuka
Pharma
Takeda, Daiichi, Astellas and more—Fierce Pharma Asia
Takeda's first-in-class narcolepsy drug won an FDA nod. Daiichi admitted to an accounting error. Astellas hit record revenue.
Angus Liu
Aug 7, 2026 8:35am
In a first, Otsuka’s Voyxact stabilizes IgAN kidney loss in ph.3
Aug 3, 2026 5:00pm
Legend Biotech, Merck, Otsuka—Fierce Pharma Asia
Jul 31, 2026 9:00am
FDA approves Otsuka’s first-in-class ADHD drug Simtriyo
Jul 27, 2026 12:42pm
AZ's China deals, Kailera-Hengrui—Fierce Pharma Asia
Jul 10, 2026 8:51am
Vera’s dual-target atacicept wins FDA approval for IgAN
Jul 7, 2026 12:23pm
